Testing two new drugs together before surgery for inflammatory breast cancer

This study is testing a combination of two medications: trastuzumab deruxtecan and durvalumab. Both drugs are already approved by the FDA for other types of cancer, but this trial is exploring whether using them together before surgery might help people with inflammatory breast cancer—a rare and aggressive type. The goal is to see if this treatment can shrink tumors and improve outcomes.

Inflammatory breast cancer is very difficult to treat, and current standard treatments don't work well enough for everyone. Researchers want to find out if this medication combination can be more effective, especially for patients whose tumors have specific HER2 markers that might respond well to these drugs.